시장보고서
상품코드
1152251

세계의 암 정밀의료 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 에코시스템별, 용도별, 지역별(2017-2027년)

Oncology Precision Medicine Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2017-2027 By Ecosystem, Precision Diagnostics, Precision Therapeutics, Applied Sciences, Hematological Malignancies, & Region

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 111 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 암 정밀의료 시장 규모는 예측 기간 중 2023-2027년에 눈부신 CAGR로 성장을 이룰 것으로 예측되고 있습니다.

암 유병률 증가나 임상시험의 치료대상 확대에 의해 암 정밀의료 수요가 높아지고 있는 것이 시장 성장을 뒷받침하고 있습니다. 또한 노인 인구에서 만성 질환의 위험이 증가하면 시장 성장을 견인하고 표적화 유전자 요법의 사용 확대가 시장 성장을 촉진 할 것으로 기대됩니다.

세계의 암 정밀의료(Oncology Precision Medicine) 시장에 대해 조사 분석 했으며, 부문별·지역별 시장 규모/점유율 예측/시장 역학/기업 개요 등 체계적인 정보를 제공하고 있습니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계 암 정밀의료 시장에 미치는 영향

제5장 VOC(고객의 목소리)

  • 암 정밀의료에의 관심
  • 암 유병률 : 성별
  • 암 유병률 : 연령층별
  • 암 유병률 : 지역별
  • 암 정밀의료를 사용하는 이점

제6장 임상시험 분석

제7장 특허 분석

제8장 세계의 암 정밀의료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 에코시스템별(정밀 진단, 정밀 치료, 응용 과학, 디지털 헬스, 정보 기술)
    • 용도별(고형 종양, 혈액 악성 종양)
    • 지역별
    • 기업별(2021년)
  • 제품 시장 맵

제9장 북미의 암 정밀의료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 에코시스템별
    • 용도별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제10장 유럽의 암 정밀의료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 에코시스템별
    • 용도별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 영국
    • 이탈리아
    • 스페인

제11장 아시아 태평양의 암 정밀의료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 에코시스템별
    • 용도별
    • 국가별
  • 아시아 태평양 : 국가별 분석
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주

제12장 남미의 암 정밀의료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 에코시스템별
    • 용도별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제13장 중동·아프리카의 암 정밀의료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 에코시스템별
    • 용도별
    • 국가별
  • MEA : 국가별 분석
    • 남아프리카
    • 사우디 아라비아
    • 아랍 에미리트 연방

제14장 시장 역학

  • 촉진 요인
  • 과제

제15장 시장 동향과 개발

제16장 SWOT 분석 : 세계 암 정밀의료 시장

제17장 경쟁 상황

  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Danaher Corporation
  • Abbott Laboratories, Inc.
  • Quest Diagnostics Inc
  • Eurofins Genomics LLC
  • Laboratory Corporation of America Holdings
  • Thermos Fischer Scientific, Inc.
  • bioMerieux SA

제18장 전략적 제안

LYJ 22.11.24

The global oncology precision medicine market is expected to grow at an impressive CAGR in the forecast period, 2023-2027. Precision medicine represent the medical approach for the prevention of disease and diagnosis which is based on genetic, environmental, and behavioural variability. It helps in illnesses susceptibility prediction, diseases diagnosis, and progression, as well as medicine prescription. It assists in taking healthcare related decisions, improving quality care, and declining inefficiencies due to the trial-and-error is also augmenting the market growth. Precision medicine is widely utilized to diagnose the chromosomal abnormalities in the foetus and cancer and works for therapy for chronic diseases. The escalating demand of oncology precision medicine methods owing to the growing prevalence of cancer and the expanding number of treatment candidates in clinical trials are fueling the growth of the market.

Increasing Risk of Chronic Diseases in Geriatric Population Drives the Market Growth

Most cancer diagnoses occur in adults over the age of 65 years which demands the accurate treatment plan for this age group. Several oncologists use recommended and available geriatric assessments to help in evaluating older patients and guide their cancer treatment planning. The concept of precision medicine extends beyond tumour-specific markers to incorporate host factors that are assessed as part of a routine geriatric assessment. Oncologists are always careful to stage the cancer in creating cancer treatment plans by giving the importance of staging the aging to ensure that cancer treatments are personalized to as per the patient condition. Assessing the health status of older adults is as important and essential to optimizing treatment as assessing tumour biology and should be included alongside other precision medicine initiatives. I applaud the authors on a well-written and insightful article on implementing geriatric assessment and encourage oncology providers to use geriatric assessments in the routine care of their older patients and to apply this knowledge to individualize their care of this growing and vulnerable population.

Rise in Use of Targeted Gene Therapy is Expected to Propel the Market Growth

Gene therapy considered as one of the most lucrative markets for precision medicine organizations. Genome sequencing is an unavoidable stage of gene therapy, the extensive investments that are being made in this field drives the growth of the precision medicine market. The increase in number of cancers is escalating the demand for gene therapy as an effective personalized treatment choice across the globe. The significant growth in the number of patients necessitates gene therapy as a potential treatment approach addressing the increasing global burden of the disease. With this, the expanding adoption of emerging genomic technologies, including NGS and high-density microarray, along with the several government initiatives is propelling the market growth.

Market Segmentation

The global oncology precision medicine market is segmented into ecosystem, application, and regional distribution. Based on the ecosystem, the market is divided into precision diagnostics, precision therapeutics, applied sciences, digital health, and information technology. Based on the precision diagnostics, the market is bifurcated into molecular diagnostics and medical imaging. Based on the precision therapeutics, the market is divided into clinical trials, cell therapy, drug discovery & research, gene therapy. Based on the applied sciences, the market is divided into genomics, pharmacogenomics, others. Based on the digital health, and information technology, the market is divided into clinical decision support systems (CDSS), big data analytics, genomics informatics, in-silico informatics, others. Based on application, the market is segmented into insect scouting, crop disease scouting, weed scouting, others. Based on application, the market is bifurcated into solid tumor and hematological malignancies. Based on solid tumor, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, others. Based on hematological malignancies, the market is divided into hodgkin lymphoma, non-hodgkin lymphoma, leukemia, others. The market analysis also studies the regional segmentation, divided among North American region, Asia-Pacific region, European region, South American region, and Middle East & African region.

Market Players

Novartis AG, F. Hoffmann-La Roche AG, Merck & Co., Inc., Danaher Corporation, Abbott Laboratories, Inc., Quest Diagnostics Inc, Eurofins Genomics LLC, Laboratory Corporation of America Holdings, Thermos Fischer Scientific, Inc., bioMerieux SA are the leading market players contributing the growth of the global oncology precision medicine market.

Report Scope:

In this report, global oncology precision medicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Oncology Precision Medicine Market, By Ecosystem:

  • Precision Diagnostics
  • Precision Therapeutics
  • Applied Sciences
  • Digital Health
  • Information Technology

Oncology Precision Medicine Market, By Precision Diagnostics:

  • Molecular Diagnostics
  • Medical Imaging

Oncology Precision Medicine Market, By Precision Therapeutics:

  • Clinical Trials
  • Cell Therapy
  • Drug Discovery & Research
  • Gene Therapy

Oncology Precision Medicine Market, By Applied Sciences:

  • Genomics
  • Pharmacogenomics
  • Others

Oncology Precision Medicine Digital Health, and Information Technology:

  • Clinical Decision Support Systems (CDSS)
  • Big Data Analytics
  • Genomics Informatics
  • In-Silico Informatics
  • Others

Oncology Precision Medicine Market, By Application:

  • Solid Tumor
  • Hematological Malignancies

Oncology Precision Medicine Market, By Solid Tumor:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

Oncology Precision Medicine Market, By Hematological Malignancies:

  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Leukemia
  • Others

Oncology Precision Medicine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Malaysia
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Poland
    • Denmark
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Peru
    • Chile
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Iraq
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global oncology precision medicine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Oncology Precision Medicine Market

5. Voice of Customer

  • 5.1. Oncology Precision Medicine Awareness
  • 5.2. Cancer Prevalence, By Gender
  • 5.3. Cancer Prevalence, By Age Group
  • 5.4. Cancer Prevalence, Region
  • 5.5. Benefits of Using Precision Medicine in Oncology

6. Clinical Trial Analysis

7. Patent Analysis

8. Global Oncology Precision Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 8.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 8.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 8.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 8.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 8.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 8.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 8.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 8.2.3. By Region
    • 8.2.4. By Company (2021)
  • 8.3. Product Market Map

9. North America Oncology Precision Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 9.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 9.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 9.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 9.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 9.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 9.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 9.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Oncology Precision Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Ecosystem
        • 9.3.1.2.2. By Application
    • 9.3.2. Mexico Oncology Precision Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Ecosystem
        • 9.3.2.2.2. By Application
    • 9.3.3. Canada Oncology Precision Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Ecosystem
        • 9.3.3.2.2. By Application

10. Europe Oncology Precision Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 10.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 10.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 10.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 10.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 10.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 10.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 10.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 10.2.3. By Country
  • 10.3. Europe: Country Analysis
    • 10.3.1. France Oncology Precision Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Ecosystem
        • 10.3.1.2.2. By Application
    • 10.3.2. Germany Oncology Precision Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Ecosystem
        • 10.3.2.2.2. By Application
    • 10.3.3. United Kingdom Oncology Precision Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Ecosystem
        • 10.3.3.2.2. By Application
    • 10.3.4. Italy Oncology Precision Medicine Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Ecosystem
        • 10.3.4.2.2. By Application
    • 10.3.5. Spain Oncology Precision Medicine Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Ecosystem
        • 10.3.5.2.2. By Application

11. Asia-Pacific Oncology Precision Medicine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 11.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 11.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 11.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 11.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 11.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 11.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 11.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 11.2.3. By Country
  • 11.3. Asia-Pacific: Country Analysis
    • 11.3.1. China Oncology Precision Medicine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Ecosystem
        • 11.3.1.2.2. By Application
    • 11.3.2. India Oncology Precision Medicine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Ecosystem
        • 11.3.2.2.2. By Application
    • 11.3.3. South Korea Oncology Precision Medicine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Ecosystem
        • 11.3.3.2.2. By Application
    • 11.3.4. Japan Oncology Precision Medicine Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Ecosystem
        • 11.3.4.2.2. By Application
    • 11.3.5. Australia Oncology Precision Medicine Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Ecosystem
        • 11.3.5.2.2. By Application

12. South America Oncology Precision Medicine Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 12.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 12.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 12.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 12.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 12.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 12.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 12.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 12.2.3. By Country
  • 12.3. South America: Country Analysis
    • 12.3.1. Brazil Oncology Precision Medicine Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Ecosystem
        • 12.3.1.2.2. By Application
    • 12.3.2. Argentina Oncology Precision Medicine Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Ecosystem
        • 12.3.2.2.2. By Application
    • 12.3.3. Colombia Oncology Precision Medicine Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Ecosystem
        • 12.3.3.2.2. By Application

13. Middle East and Africa Oncology Precision Medicine Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value
  • 13.2. Market Share & Forecast
    • 13.2.1. By Ecosystem (Precision Diagnostics, Precision Therapeutics, Applied Sciences, Digital Health, and Information Technology)
      • 13.2.1.1. Precision Diagnostics (Molecular Diagnostics v/s Medical Imaging)
      • 13.2.1.2. Precision Therapeutics (Clinical Trials, Cell Therapy, Drug Discovery & Research, Gene Therapy)
      • 13.2.1.3. Applied Sciences (Genomics, Pharmacogenomics, Others)
      • 13.2.1.4. Digital Health, and Information Technology (Clinical Decision Support Systems (CDSS), Big Data Analytics, Genomics Informatics, In-Silico Informatics, Others)
    • 13.2.2. By Application (Solid Tumor v/s Hematological Malignancies)
      • 13.2.2.1. Solid Tumor (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others)
      • 13.2.2.2. Hematological Malignancies (Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Leukemia, Others)
    • 13.2.3. By Country
  • 13.3. MEA: Country Analysis
    • 13.3.1. South Africa Oncology Precision Medicine Market Outlook
      • 13.3.1.1. Market Size & Forecast
        • 13.3.1.1.1. By Value
      • 13.3.1.2. Market Share & Forecast
        • 13.3.1.2.1. By Ecosystem
        • 13.3.1.2.2. By Application
    • 13.3.2. Saudi Arabia Oncology Precision Medicine Market Outlook
      • 13.3.2.1. Market Size & Forecast
        • 13.3.2.1.1. By Value
      • 13.3.2.2. Market Share & Forecast
        • 13.3.2.2.1. By Ecosystem
        • 13.3.2.2.2. By Application
    • 13.3.3. UAE Oncology Precision Medicine Market Outlook
      • 13.3.3.1. Market Size & Forecast
        • 13.3.3.1.1. By Value
      • 13.3.3.2. Market Share & Forecast
        • 13.3.3.2.1. By Ecosystem
        • 13.3.3.2.2. By Application

14. Market Dynamics

  • 14.1. Drivers
  • 14.2. Challenges

15. Market Trends & Developments

16. SWOT Analysis: Global Oncology Precision Medicine Market

17. Competitive Landscape (Inclusive of SWOT Analysis of Players Profiled)

  • 17.1. Novartis AG
  • 17.2. F. Hoffmann-La Roche AG
  • 17.3. Merck & Co., Inc.
  • 17.4. Danaher Corporation
  • 17.5. Abbott Laboratories, Inc.
  • 17.6. Quest Diagnostics Inc
  • 17.7. Eurofins Genomics LLC
  • 17.8. Laboratory Corporation of America Holdings
  • 17.9. Thermos Fischer Scientific, Inc.
  • 17.10. bioMerieux SA

18. Strategic Recommendations

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제